These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 8294389)

  • 1. Serotonin reuptake blockers for the treatment of obsessional jealousy.
    Stein DJ; Hollander E; Josephson SC
    J Clin Psychiatry; 1994 Jan; 55(1):30-3. PubMed ID: 8294389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
    Barr LC; Goodman WK; Anand A; McDougle CJ; Price LH
    Am J Psychiatry; 1997 Sep; 154(9):1293-5. PubMed ID: 9286191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Will pindolol augment the response to a serotonin reuptake inhibitor in obsessive-compulsive disorder?
    Koran LM; Mueller K; Maloney A
    J Clin Psychopharmacol; 1996 Jun; 16(3):253-4. PubMed ID: 8784659
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacologic management of obsessive-compulsive disorder.
    Jackson CW; Morton WA; Lydiard RB
    South Med J; 1994 Mar; 87(3):310-21. PubMed ID: 8134850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obsessional jealousy: unusual presentation.
    Agarwal AL; Sharma V; Biswas D
    Aust N Z J Psychiatry; 2008 Dec; 42(12):1068. PubMed ID: 19016096
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacologic treatment of obsessive-compulsive disorder: comparative studies.
    Flament MF; Bisserbe JC
    J Clin Psychiatry; 1997; 58 Suppl 12():18-22. PubMed ID: 9393392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.
    Greist JH; Jefferson JW; Kobak KA; Katzelnick DJ; Serlin RC
    Arch Gen Psychiatry; 1995 Jan; 52(1):53-60. PubMed ID: 7811162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory.
    Jenike MA; Hyman S; Baer L; Holland A; Minichiello WE; Buttolph L; Summergrad P; Seymour R; Ricciardi J
    Am J Psychiatry; 1990 Sep; 147(9):1209-15. PubMed ID: 2143637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.
    Piccinelli M; Pini S; Bellantuono C; Wilkinson G
    Br J Psychiatry; 1995 Apr; 166(4):424-43. PubMed ID: 7795913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sertraline and mental retardation with obsessive-compulsive disorder.
    Wiener K; Lamberti JS
    Am J Psychiatry; 1993 Aug; 150(8):1270. PubMed ID: 8328577
    [No Abstract]   [Full Text] [Related]  

  • 12. Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies.
    Chouinard G
    Int Clin Psychopharmacol; 1992 Oct; 7 Suppl 2():37-41. PubMed ID: 1484177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible?
    Todorov C; Freeston MH; Borgeat F
    Can J Psychiatry; 2000 Apr; 45(3):257-62. PubMed ID: 10779882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy of obsessive compulsive disorder.
    Goodman WK; McDougle CJ; Price LH
    J Clin Psychiatry; 1992 Apr; 53 Suppl():29-37. PubMed ID: 1532962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obsessive-compulsive disorder: a new perspective in diagnosis and treatment.
    Lydiard RB
    Int Clin Psychopharmacol; 1994 Jun; 9 Suppl 3():33-7. PubMed ID: 7963449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacotherapy of obsessive-compulsive disorder.
    McDougle CJ; Goodman WK; Price LH
    Pharmacopsychiatry; 1993 May; 26 Suppl 1():24-9. PubMed ID: 8378419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment.
    Hollander E; DeCaria CM; Schneier FR; Schneier HA; Liebowitz MR; Klein DF
    J Clin Psychiatry; 1990 Mar; 51(3):119-23. PubMed ID: 2106515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inability to cry during SRI treatment.
    Oleshansky MA; Labbate LA
    J Clin Psychiatry; 1996 Dec; 57(12):593. PubMed ID: 9010124
    [No Abstract]   [Full Text] [Related]  

  • 19. Selective serotonin reuptake inhibitors in OCD.
    Montgomery SA; Bullock T; Fineberg N; Montgomery D
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():255A-256A. PubMed ID: 1498831
    [No Abstract]   [Full Text] [Related]  

  • 20. A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.
    Carpenter LL; McDougle CJ; Epperson CN; Price LH
    Drug Saf; 1996 Aug; 15(2):116-34. PubMed ID: 8884163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.